UBS Group AG Cuts Stake in Alpha Teknova, Inc. $TKNO

UBS Group AG lessened its stake in Alpha Teknova, Inc. (NASDAQ:TKNO) by 50.9% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 737,265 shares of the company’s stock after selling 764,879 shares during the quarter. UBS Group AG’s holdings in Alpha Teknova were worth $2,802,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in TKNO. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in shares of Alpha Teknova in the 2nd quarter valued at about $29,000. JPMorgan Chase & Co. increased its holdings in shares of Alpha Teknova by 123.1% in the 2nd quarter. JPMorgan Chase & Co. now owns 8,163 shares of the company’s stock valued at $40,000 after purchasing an additional 4,504 shares in the last quarter. Larson Financial Group LLC increased its holdings in shares of Alpha Teknova by 58.5% in the 3rd quarter. Larson Financial Group LLC now owns 9,387 shares of the company’s stock valued at $58,000 after purchasing an additional 3,464 shares in the last quarter. Sherbrooke Park Advisers LLC purchased a new position in shares of Alpha Teknova in the 3rd quarter valued at about $94,000. Finally, New York State Common Retirement Fund purchased a new position in shares of Alpha Teknova in the 2nd quarter valued at about $96,000. Hedge funds and other institutional investors own 13.81% of the company’s stock.

Alpha Teknova Stock Performance

Shares of TKNO opened at $3.89 on Tuesday. The company has a 50-day simple moving average of $3.21 and a 200-day simple moving average of $3.45. The company has a quick ratio of 3.60, a current ratio of 4.59 and a debt-to-equity ratio of 0.20. The company has a market capitalization of $208.54 million, a PE ratio of -12.16 and a beta of 0.47. Alpha Teknova, Inc. has a 52-week low of $1.91 and a 52-week high of $6.68.

Alpha Teknova (NASDAQ:TKNO) last announced its quarterly earnings results on Wednesday, May 6th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.01. Alpha Teknova had a negative net margin of 41.07% and a negative return on equity of 24.32%. The business had revenue of $11.08 million during the quarter, compared to the consensus estimate of $10.23 million.

Insiders Place Their Bets

In other Alpha Teknova news, CEO Stephen Gunstream bought 26,000 shares of the company’s stock in a transaction on Friday, March 6th. The stock was purchased at an average cost of $2.15 per share, for a total transaction of $55,900.00. Following the acquisition, the chief executive officer owned 269,497 shares of the company’s stock, valued at $579,418.55. The trade was a 10.68% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 12.50% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Alpha Teknova in a report on Monday, April 20th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Alpha Teknova has an average rating of “Hold” and an average price target of $8.00.

Alpha Teknova Company Profile

Alpha Teknova, Inc (NASDAQ: TKNO) is a life science tools and reagents company that develops, manufactures and distributes proprietary products to support research, drug discovery and biomanufacturing. Its offerings target academic institutions, pharmaceutical and biotechnology firms, and diagnostic developers, with a focus on high-purity reagents and optimized workflows designed to accelerate molecular biology and protein science applications.

The company’s portfolio includes molecular biology reagents, cell culture buffers, in vitro translation kits, custom recombinant proteins, high-throughput screening buffers and other specialized formulations.